Catalent, Inc. (CTLT) Position Boosted by OxFORD Asset Management LLP
OxFORD Asset Management LLP boosted its holdings in shares of Catalent, Inc. (NYSE:CTLT) by 7.2% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 83,032 shares of the company’s stock after acquiring an additional 5,605 shares during the quarter. OxFORD Asset Management LLP owned 0.06% of Catalent worth $3,280,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Janus Henderson Group PLC purchased a new stake in shares of Catalent in the 2nd quarter worth $239,629,000. BlackRock Inc. lifted its holdings in shares of Catalent by 15.2% in the 2nd quarter. BlackRock Inc. now owns 17,512,661 shares of the company’s stock worth $614,695,000 after buying an additional 2,316,849 shares during the period. Eagle Asset Management Inc. lifted its stake in shares of Catalent by 290.9% during the 3rd quarter. Eagle Asset Management Inc. now owns 1,153,710 shares of the company’s stock worth $47,636,000 after purchasing an additional 858,600 shares during the last quarter. AJO LP purchased a new stake in shares of Catalent during the 2nd quarter worth $26,130,000. Finally, Macquarie Group Ltd. lifted its stake in shares of Catalent by 60.2% during the 2nd quarter. Macquarie Group Ltd. now owns 1,786,764 shares of the company’s stock worth $62,715,000 after purchasing an additional 671,429 shares during the last quarter. Institutional investors own 99.49% of the company’s stock.
In other Catalent news, Director Uwe Roehrhoff bought 7,500 shares of Catalent stock in a transaction that occurred on Tuesday, November 21st. The shares were bought at an average cost of $39.22 per share, with a total value of $294,150.00. The transaction was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 1.70% of the company’s stock.
CTLT has been the subject of a number of analyst reports. Zacks Investment Research cut Catalent from a “buy” rating to a “hold” rating in a research note on Friday, November 3rd. Wells Fargo & Company restated an “outperform” rating and set a $39.00 price objective (up from $30.00) on shares of Catalent in a research note on Thursday, August 31st. J P Morgan Chase & Co restated a “buy” rating and set a $40.00 price objective on shares of Catalent in a research note on Tuesday, August 29th. ValuEngine cut Catalent from a “buy” rating to a “hold” rating in a research note on Friday, December 1st. Finally, Needham & Company LLC restated a “hold” rating on shares of Catalent in a research note on Monday, October 23rd. Four equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Catalent currently has a consensus rating of “Buy” and an average target price of $44.25.
Catalent, Inc. (NYSE CTLT) opened at $39.72 on Friday. Catalent, Inc. has a 1 year low of $24.30 and a 1 year high of $43.39. The stock has a market capitalization of $5,226.69, a PE ratio of 27.51, a P/E/G ratio of 2.53 and a beta of 1.41. The company has a debt-to-equity ratio of 2.01, a quick ratio of 2.49 and a current ratio of 2.91.
Catalent (NYSE:CTLT) last announced its earnings results on Monday, November 6th. The company reported $0.21 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.20 by $0.01. Catalent had a return on equity of 23.97% and a net margin of 5.01%. The company had revenue of $543.90 million for the quarter, compared to analyst estimates of $490.75 million. During the same period in the prior year, the company posted $0.16 EPS. The firm’s quarterly revenue was up 23.0% compared to the same quarter last year. equities analysts predict that Catalent, Inc. will post 1.46 earnings per share for the current fiscal year.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Receive News & Ratings for Catalent Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.